A double-blind, randomized, multicenter, placebo-controlled, parallel-groups efficacy and safety extension study of MK-0928 [gaboxadol] in the treatment of adult outpatients with primary insomnia
Latest Information Update: 05 May 2022
At a glance
- Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
- Indications Insomnia
- Focus Registrational; Therapeutic Use
- Sponsors Lundbeck A/S; Merck & Co
- 14 Dec 2005 New trial record.